What is the clinical evidence from this study?

Study design: Review. Population: Bleeding complications on anticoagulant therapy. Intervention: Anticoagulant reversal and bleeding management.

What question did this study set out to answer?

To review supportive strategies, specific reversal agents, and considerations for restarting therapy following major bleeding complications associated with oral anticoagulants.

April 1, 2017Seminars in Thrombosis and Hemostasis

Bleeding Complications and Management on anticoagulant therapy

View Full Paper

Ask AI

Bookmark

Key result

This review outlines strategies for managing major bleeding in patients on oral anticoagulants, including the use of specific antidotes like idarucizumab and andexanet-α, and posthemorrhage care.

Key Points

To review supportive strategies, specific reversal agents, and considerations for restarting therapy following major bleeding complications associated with oral anticoagulants.
Reviewed post hoc analyses from phase III pivotal clinical trials of non-vitamin K antagonist oral anticoagulants (NOACs).
Evaluated emerging safety and efficacy data for targeted reversal agents (idarucizumab and andexanet-α) alongside prothrombin complex concentrates (PCCs).
Specific antidotes such as idarucizumab for dabigatran and andexanet-α for factor Xa inhibitors offer targeted reversal of anticoagulation during major hemorrhage, while regular or activated prothrombin complex concentrates serve as viable alternative agents when specific antidotes are unavailable.
Resumption of anticoagulation following successful hemostasis requires careful clinical evaluation, as patients face substantial prothrombotic risks and potential thromboembolic complications within the first month post-hemorrhage despite weak guideline recommendations.

Structured PICO

Population

Patients treated with anticoagulants experiencing major bleeding complications

Intervention

Management strategies including supportive measures, specific antidotes (idarucizumab, andexanet-α), and prothrombin complex concentrates

This review outlines strategies for managing NOAC-associated major bleeding, including the use of specific antidotes and considerations for the timing of anticoagulation resumption.

Limitations

Guidelines for the resumption of anticoagulation after hemorrhage are very weak or unavailable.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Synthesizes current protocols for NOAC reversal in major bleeding; leaves open.

Cite This Study

Sam Schulman (2017) conducted a review in Bleeding complications on anticoagulant therapy. Anticoagulant reversal and bleeding management was evaluated. This review outlines strategies for managing major bleeding in patients on oral anticoagulants, including the use of specific antidotes like idarucizumab and andexanet-α, and posthemorrhage care.

synapsesocial.com/papers/6a86e4235ee22a1e35cb9bba https://doi.org/10.1055/s-0037-1602377

View Full Paper

Ask AI

Bookmark

Bleeding Complications and Management on anticoagulant therapy

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Bleeding Complications and Management on anticoagulant therapy

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Also Consider

Also Consider